Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

299.77 6.47 −2.11%
Market cap
$14.6B
P/E
0.0×
Fwd P/E
29.6×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
1.91 2.46 2.10 2.72
P/FCF ratio
14.16 19.07 21.58 29.39
P/Operating CF
36.01 67.02 205.57 60.60
P/B ratio
2.26 3.12 2.87 3.83
EV/Sales
2.41 2.94 2.71 3.33
EV/EBITDA
12.36 19.90 18.65 24.09
EV/FCF
17.81 22.78 27.90 35.94
Current Ratio
1.37 1.29 1.36 1.35
Net Debt/EBITDA
9.04 (47.87) 13.21 12.97
Debt/Equity
0.64 0.67 0.90 0.92
Earnings Yield
(0.99%) (1.48%) (2.17%) (2.13%)
Free Cash Flow Yield
7.06% 5.24% 4.63% 3.40%
Free Cash Flow per Share
3.62 1.18 (0.30) 3.09
Book value per Share
69.30 63.96 60.19 59.27
Free Cash Flow
178.25 58.57 (14.83) 148.62
EV/EBIT
68.70 469.42 155.10 147.77
Other line items

Show all line items

Columns are period end dates